alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORN

I

A

IT IS SO ORDERED

Judge Edward J. Davila

2/16/2017

Case 5:17-cv-00141-EJD Document 29 Filed 02/16/17 Page 1 of 2
Case 5:17-cv-00141-EJD Document 29 Filed 02/16/17 Page 2 of 2
<PAGE>
                                                                    EXHIBIT 32.1

                          TEXTRON FINANCIAL CORPORATION

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Textron Financial Corporation (the
"Company") on Form 10-Q for the period ended March 31, 2006 as filed with the
Securities and Exchange Commission on the Date hereof (the "Report"), I, Ted R.
French, Chairman and Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:

      (1)   The Report fully complies with the requirements of section 13(a) or
            15(d) of the Securities Exchange Act of 1934; and

      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Company.

                                      Textron Financial Corporation

Date: May 5, 2006                     /s/ Ted R. French
                                     ---------------------------------------
                                      Ted R. French
                                      Chairman and Chief Executive Officer
JUDGMENT

Court of Appeals 

 

First District of Texas 

NO. 01-21-00539-CV

JAMES CLIFFORD WALKER, Appellant

V.

FREDERICK LUNENBURG AND MELODY LUNENBURG, Appellees

Appeal from the 412th Judicial District Court of Brazoria County. (Tr. Ct. No. 102095-

CV).

This case is an appeal from the trial court’s August 19, 2021 order. After 

submitting the case on the appellate record and the arguments properly raised by the parties, 

the Court holds that the trial court’s order contains no reversible error. Accordingly, the 

Court affirms the trial court’s order.

The Court orders that the appellant, James Clifford Walker, pay all appellate costs.

The Court orders that this decision be certified below for observance.

Judgment rendered October 31, 2023.

Panel consists of Chief Justice Adams and Justices Hightower and Countiss. Opinion 

delivered by Justice Hightower.
Joshua ZEIGLER, DOC #S05621, Appellant, v. STATE of Florida, Appellee.

Case No. 2D18-4770

District Court of Appeal of Florida, Second District.

Opinion filed July 17, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Joshua A. MCGRAIL, Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D18-4710

District Court of Appeal of Florida, Second District.

May 29, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
Dietary

Supplement

Dietary

Supplement

Dietary

Supplement DietarySupplement DietarySupplement

Dietary

Supplement

Dietary Supplement Dietary Supplement

Dietary

Supplement

Dietary

Supplement

FDA Regulates

Even though FDA does not approve 

dietary supplements, there are 

product manufacturing and 

labeling requirements in place 

that supplement companies are 

required to follow.

FDA Takes Action

When a product is found to be unsafe or otherwise 

not in compliance with FDA requirements, FDA can:

• Work with the company to bring the product 

into compliance.

• Ask the company to voluntarily recall the product.

• Take action to remove a dangerous product from 

the market.

The Law

The Dietary Supplement Health and Education Act of 1994 

(DSHEA) defined dietary supplements and set out FDA’s 

authority regarding these products. Under DSHEA:

• FDA does not have the authority to approve 

dietary supplements for safety and effectiveness or 

their labeling before they are sold in stores or online.

• Dietary supplement companies are responsible for 

ensuring that their products are safe and label claims 

are truthful and substantiated.

• Dietary supplement companies can introduce new 

dietary supplements to the market without receiving 

approval from FDA. In fact, they often can introduce 

dietary supplements to the market without even 

notifying FDA.

 May 2022

Dietary Supplements: 

How FDA Helps Keep You Safe

DSHEA

Dietary

Supplement

Dietary

Supplement

Periodically inspecting dietary 

supplement manufacturing facilities 

to verify that companies are meeting 

all manufacturing and labeling 

requirements.

Monitoring adverse event reports 

and complaints received from 

industry, healthcare professionals, 

and consumers.

FDA oversees the dietary supplement 

marketplace by:

Learn more at www.fda.gov/dietarysupplements.
In re Robert Earl TIPPENS, Jr., petitioner.

No. 12-8665.

Supreme Court of the United States

May 28, 2013.

Petition for rehearing denied.
Wilmario TRUEBLOOD, Appellant, v. STATE of Florida, Appellee.

Nos. 1D17-4307 1D17-4308

District Court of Appeal of Florida, First District.

June 20, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Chad SPLAWN, petitioner, v. Rick THALER, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 12-9358.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Dokiman sa te devlope pa Biwo FDA nan 

Sante Fanm (OWH) ak Asosyasyon 

Nasyonal nan Chain Magazen Dwog 

(NACDS).

Prè de 30% a 50% de moun ki sèvi ak 

medikaman pa sèvi ak yo jan yo mande. 

Sa lakòz plis vizit doktè, rete lopital, pèdi 

salè, ak preskripsyon chanje. Tout bagay 

sa yo koute Ameriken plis pase $100 milya 

dola chak ane.

Granmoun souvan pran swen medikaman 

pou tout fanmi ansanm ak tèt yo. Se 

konsa, nou bezwen li etikèt la, evite 

pwoblèm, poze kesyon, epi kenbe yon 

dosye.

1. LI ETIKET LA

Anvan ou pran nenpot medikaman, li etiket 

la. Etiket la ta dwe montre:

Lis Engredyan - Si ou konnen ou fè alèji 

ak anyen ki nan medikaman an, pa sèvi 

avec li. Mande doktè ou oswa famasyen 

ou pou yon medikaman diferan.

Avetisman - Li sa ya avec anpil atansyon.

Dat de ekspirasyon - Pa itilize yon 

medikaman apre dat ki sou boutey la. Li 

ka pa byen travay.

Pou plis enfòmasyon sou medikaman ou, 

mande famasyen ou.

2. EVITE PWOBLEM

Medikaman ka lakòz pwoblèm oswa efè 

segondè tankou dòmi, vomisman, senyen, 

tèt fè mal, oswa gratèl. Mande 

enfòmasyon sou efè segondè medikaman 

w ap pran yo. Pale ak doktè ou, famasyen, 

oswa enfimyè ou.

Oganize medikaman ou.

Pa sote pran medikaman ou.

Pa pataje medikaman.

Pa pran medikaman nan fe nwa.

 ITILIZE MEDIKAMAN AK ENTELIJANS

TET OU ... POU MOUN KI BEZWEN OU

PRAN TAN POU PRAN SWEN

Biwo nan Sante Fanm

www.fda.gov/womens

PRAN TAN POU PRAN SWEN

TET OU...POU MOUN KI BEZWEN OU

MEDIKAMAN 

MWEN
3. MANDE KESYON

Ki nom medikaman an?

•

•

Eske gen yon jenerik?

• Pou ki sa map pran medikaman sa?

• Ki le mwen ta dwe pran li?

• Eske mwen ta dwe pran sou yon lestomak

vid oswa avek manje?

• Eske li san danje pou bwe alkol avek li?

• Si mwen bliye pran li, ki sa pou mwen fe?

• Konbyen mwen ta dwe pran?

• Pou konbyen tan pou mwen pran?

• Pou ki pwoblem mwen ta dwe gade?

Si ou ansent oswa wapbay tete, chèche 

konsèy yon pwofesyonèl sante anvan ou 

pran nenpòt medikaman oswa sipleman. 

Pale ak doktè ou, famasyen, oswa enfimyè 

ou. Li ap kontan pou ede ou

Lis nenpot aleji 

Dokte

Nimewo Telefon

4. KENBE YON DOSYE

MEDIKAMAN WAP ITILIZE

Tcheke bwat pou sa wap itilize yo:

Aspirin oswa lòt medikaman 

doulè / maltèt / lafyèv

Anti-asid pou aleji 

Medikaman

Medikaman fwad

Medikaman tous

Rejim 

Grenn/sipleman, 

laksatif

Vitamins

Minerals

Erb

Lot Yo

NOM:

LISTE PRESKRIPSYON MEDIKAMEN OU

KONBYEN POU

 MWEN PRAN

KI LE POU 

MWEN PRAN LI

POU KISA 

MWEN ITILIZE LI RENOUVELMAN

1 grenn

400 mg

3 fwa pa jou 

apre ou manje Atrit 2

NOM MEDIKA

DAT MAN MWEN

EGZANP XXXX

KENBE SA NAN VALIZ OU OSWA POCH OU EPI MONTRE LI BAY DOKTE OU, FAMASYEN, OSWA 

ENFIMYE OU.

Fe dokte, famasyen oswa enfimye ou rapote gwo pwoblem medikaman bay FDA nan 1-800-FDA-1088.
Lamont JACKSON, petitioner, v. Michael D. CREWS, Secretary, Florida Department of Corrections, et al.

No. 12-8488.

Supreme Court of the United States

April 1, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
#### Ferman Alvin RUPPE, Jr., Plaintiff—Appellant, v. Gene JOHNSON, Director, VDOC; Fred Schilling, Director; Happy Smith, Dr., WRSP; G. Hobbs, Nurse, Lpn, WRSP; Nurse Hillman, WRSP; Nurse Mullins, WRSP; S.K. Young, Warden, WRSP; Nurse Hensley, WRSP, Defendants—Appellees.

No. 03-7908.

United States Court of Appeals, Fourth Circuit.

Submitted April 29, 2004.

Decided May 4, 2004.

Ferman Alvin Ruppe, Jr., Appellant pro se.

Before LUTTIG, WILLIAMS, and SHEDD, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).

PER CURIAM:

Ferman Alvin Ruppe, Jr., appeals the district court’s order dismissing without prejudice his 42 U.S.C. § 1983 (2000) complaint. We have reviewed the record and find the district court did not abuse its discretion in dismissing the complaint. Accordingly, we grant leave to proceed in forma pauperis and affirm on the reasoning of the district court. *See Ruppe v. Johnson,*No. CA-03-581-7 (W.D.Va. Oct. 31, 2003). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED*
<TABLE> <S> <C>


<ARTICLE>                                            9
<MULTIPLIER>                                     1,000
<RESTATED>
       
<S>                             <C>
<PERIOD-TYPE>                   6-mos
<FISCAL-YEAR-END>                          Dec-31-1996 
<PERIOD-START>                             Jan-01-1996
<PERIOD-END>                               Jun-30-1996
<CASH>                                         111,083
<INT-BEARING-DEPOSITS>                           5,215
<FED-FUNDS-SOLD>                                59,700
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                    503,168
<INVESTMENTS-CARRYING>                          29,749
<INVESTMENTS-MARKET>                                 0
<LOANS>                                      2,695,520
<ALLOWANCE>                                    (45,921)
<TOTAL-ASSETS>                               3,536,020
<DEPOSITS>                                   3,115,866
<SHORT-TERM>                                   136,957
<LIABILITIES-OTHER>                             42,704
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     68,063
<COMMON>                                         5,915
<OTHER-SE>                                     166,515
<TOTAL-LIABILITIES-AND-EQUITY>               3,536,020 
<INTEREST-LOAN>                                116,061
<INTEREST-INVEST>                               13,224
<INTEREST-OTHER>                                 2,824
<INTEREST-TOTAL>                               132,109
<INTEREST-DEPOSIT>                              62,974
<INTEREST-EXPENSE>                              71,868
<INTEREST-INCOME-NET>                           60,241
<LOAN-LOSSES>                                    6,204
<SECURITIES-GAINS>                                 204
<EXPENSE-OTHER>                                 49,080
<INCOME-PRETAX>                                 15,025
<INCOME-PRE-EXTRAORDINARY>                      15,025 
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     9,907
<EPS-PRIMARY>                                   300.27
<EPS-DILUTED>                                   291.26
<YIELD-ACTUAL>                                    8.00
<LOANS-NON>                                     36,464
<LOANS-PAST>                                     4,880
<LOANS-TROUBLED>                                   210
<LOANS-PROBLEM>                                 35,426
<ALLOWANCE-OPEN>                                52,665
<CHARGE-OFFS>                                  (16,434)
<RECOVERIES>                                     3,486
<ALLOWANCE-CLOSE>                               45,921
<ALLOWANCE-DOMESTIC>                            45,921
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        


</TABLE>
GONZÁLEZ DECL. ISO DEFTS’ JOINT MOTION TO COMPEL ARBITRATION

Case No. 3:17-cv-00939-WHA 

pa-1779382 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

MICHAEL A. JACOBS (CA SBN 111664)

MJacobs@mofo.com

ARTURO J. GONZÁLEZ (CA SBN 121490) 

AGonzalez@mofo.com

ERIC A. TATE (CA SBN 178719) 

ETate@mofo.com

MORRISON & FOERSTER LLP

425 Market Street 

San Francisco, California 94105-2482 

Telephone: 415.268.7000 

Facsimile: 415.268.7522 

Attorneys for Defendants 

UBER TECHNOLOGIES, INC., 

OTTOMOTTO LLC, and OTTO TRUCKING LLC 

KAREN L. DUNN (Pro Hac Vice app. pending) 

kdunn@bsfllp.com

HAMISH P.M. HUME (Pro Hac Vice app. pending) 

hhume@bsfllp.com

BOIES SCHILLER FLEXNER LLP 

1401 New York Avenue, N.W. 

Washington DC 20005 

Telephone: 202.237.2727 

Facsimile: 202.237.6131 

Attorneys for Defendants 

UBER TECHNOLOGIES, INC. 

and OTTOMOTTO LLC 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO DIVISION 

WAYMO LLC, 

Plaintiff, 

v. 

UBER TECHNOLOGIES, INC., 

OTTOMOTTO LLC; OTTO TRUCKING LLC, 

Defendants. 

Case No. 3:17-cv-00939-WHA

DECLARATION OF ARTURO J. 

GONZÁLEZ IN SUPPORT OF 

DEFENDANTS’ JOINT MOTION TO 

COMPEL ARBITRATION OF, AND 

TO STAY, TRADE SECRET AND 

UCL CLAIMS [9 U.S.C. §§ 3, 4] 

Date: May 4, 2017 

Time: 8:00 a.m. 

Ctrm: 8, 19th Floor 

Judge: The Honorable William H. Alsup 

Trial Date: October 2, 2017

REDACTED VERSION OF DOCUMENT SUBMITTED UNDER SEAL

Case 3:17-cv-00939-WHA Document 115-1 Filed 03/27/17 Page 1 of 3
GONZÁLEZ DECL. ISO DEFTS’ JOINT MOTION TO COMPEL ARBITRATION

Case No. 3:17-cv-00939-WHA 1

pa-1779382 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

I, Arturo J. González, declare as follows: 

1. I am a member of the bar of the State of California and a partner with Morrison & 

Foerster LLP, counsel of record for Defendants Uber Technologies, Inc., Ottomotto LLC, and 

Otto Trucking LLC in this action. I am admitted to practice before this Court. I submit this 

declaration in support of Defendants’ Joint Motion to Compel Arbitration of, and to Stay, Trade 

Secret and UCL Claims. I have personal knowledge of the facts stated herein and, if called as a 

witness, I could and would testify competently as to these facts. 

2. 

3.

 

4.

5.

Case 3:17-cv-00939-WHA Document 115-1 Filed 03/27/17 Page 2 of 3
GONZÁLEZ DECL. ISO DEFTS’ JOINT MOTION TO COMPEL ARBITRATION

Case No. 3:17-cv-00939-WHA 2

pa-1779382 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

6. This week, 

 based upon the broad arbitration provisions in Levandowski’s employment 

agreements with Waymo. 

I declare until penalty of perjury under the laws of the United States that the foregoing is 

true and correct. Executed this 27th day of March, 2017, in San Francisco, California. 

 /s/ Arturo J. González 

Arturo J. González 

Case 3:17-cv-00939-WHA Document 115-1 Filed 03/27/17 Page 3 of 3
Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 1 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 2 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 3 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 4 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 5 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 6 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 7 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 8 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 9 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 10 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 11 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 12 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 13 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 14 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 15 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 16 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 17 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 18 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 19 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 20 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 21 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 22 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 23 of 24

Case 3:17-cv-00935-JSC   Document 1-1   Filed 02/23/17   Page 24 of 24
I 

109TH CONGRESS 

1ST SESSION H. R. 1274 

To suspend temporarily the duty on amyl-anthraquinone. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 14, 2005 

Mr. BAIRD introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL 

To suspend temporarily the duty on amyl-anthraquinone. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. AMYL-ANTHRAQUINONE. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.04.22 9, 10-Anthracenedione (CAS 

No. 13936–21–5) (provided 

for in subheading 

2914.69.90 in pure form or 

3824.90.28 in 50% solution) Free No change No change On or before 

12/31/2006 ’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 this section shall apply with respect to goods entered, or 
2 

•HR 1274 IH 

1 withdrawn from warehouse for consumption, on or after 

2 the 15th day after the date of enactment of this Act. 

Æ
NUMBERS 13-23-00227-CV

COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI – EDINBURG

____________________________________________________________

EDNA MASONIC LODGE #767, Appellant,

v.

DAMON MOORE THE CHIEF 

APPRAISER JACKSON CENTRAL 

APPRAISAL DISTRICT, Appellee. 

____________________________________________________________

On appeal from the 267th District Court

of Jackson County, Texas.

____________________________________________________________

MEMORANDUM OPINION

Before Chief Justice Contreras and Justices Benavides and Longoria

Memorandum Opinion by Justice Benavides

This cause is before the Court on a joint motion for disposition and appellant’s 

motion to waive fees. The parties, having reached an agreement to compromise and 

settle their differences, request entry of an agreed judgment. The joint motion is construed 

as a joint motion to vacate and remand. See TEX. R. APP. PRO. 43.2 (e). 
2

The Court, having considered the documents on file and the joint motion to vacate 

and remand, is of the opinion that the motion should be granted. See TEX. R. APP. P. 

42.1(a). We vacate the subject order, without reference to the merits, dismiss the appeal, 

and remand the case to the trial court for entry of the agreed, final judgment, in 

accordance with the parties’ agreement. See Tex. R. App. P. 42.1(a)(2)(B), 43.2(d), (e).

Additionally, and in accordance with the parties’ agreement, we grant the motion 

to waive costs in part and deny in part. All costs already incurred in the appeal will be 

taxed against the party incurring the same. See TEX. R. APP. P. 42.1(d). Having dismissed 

the appeal at the parties’ request, no motion for rehearing will be entertained and there 

shall be no future costs in assessed by this Court.

GINA M. BENAVIDES

Justice

Delivered and filed on

the 6th day of July, 2023.
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SCOTT JOHNSON,

Plaintiff,

v.

EMILE S. NIJMEH, et al.,

Defendants.

Case No. 17-cv-00038-NC 

ORDER TO SHOW CAUSE

On May 31, 2017, the Court ordered defendants Emile S. Nijmeh, Sawsan A. 

Nijmeh, Typografiks Inc., and Reza Inc., to submit a case management statement advising 

the Court and plaintiff Scott Johnson of their intent to defend the case. Dkt. No. 28. No 

defendant responded. The clerk has already entered default against defendants 

Typografiks, Inc. and Reza, Inc. Dkt. Nos. 11, 25.

On September 1, 2017, the Court ordered Johnson to file a motion for default 

judgment and proposed order by September 14, 2017. Dkt. No. 29. Johnson has not filed 

the motion and proposed order or otherwise responded. Therefore, the Court ORDERS 

Johnson to SHOW CAUSE why the case should not be dismissed for failure to prosecute. 

Johnson must respond to this order within 14 days, by October 30, 2017.

IT IS SO ORDERED.

Dated: October 16, 2017 _____________________________________

NATHANAEL M. COUSINS

United States Magistrate Judge
2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SCOTT JOHNSON,

Plaintiff,

v.

EMILE S. NIJMEH, et al.,

Defendants.

Case No. 17-cv-00038-NC 

CERTIFICATE OF SERVICE

I, the undersigned, hereby certify that I am an employee in the Office of the Clerk, U.S. 

District Court, Northern District of California.

That on October 16, 2017, I SERVED a true and correct copy(ies) of the attached, by 

placing said copy(ies) in a postage paid envelope addressed to the person(s) hereinafter listed, by 

depositing said envelope in the U.S. Mail, or by placing said copy(ies) into an inter-office delivery 

receptacle located in the Clerk's office.

Emile S. Nijmeh

2601 Carol Drive

San Jose, CA 95125 

Dated: October 16, 2017

Susan Y. Soong

Clerk, United States District Court

By:________________________

Lili M Harrell, Deputy Clerk to the 

Honorable NATHANAEL M. COUSINS